Mr. Mao Hua, Partner and Managing Director of Frost & Sullivan Greater China, delivered a keynote report
Since 2019, Frost & Sullivan has participated in the Healthcare Venture Capital Conference for three consecutive years. At the sixth Healthcare Venture Capital Conference in 2021, Frost & Sullivan continued to collaborate with the conference organizers and well-known listed service providers to successfully host the 'Capital Market Innovation Services Forum' on September 26th. At the event, Mr. Mao Hua, Partner and Managing Director of Frost & Sullivan Greater China, delivered a keynote report on the outlook for the pharmaceutical industry in China in the post-pandemic era.
Mr. Mao Huaie started fromBispecific antibody industry, mRNA technology platform, small nucleic acid drug industry, cell and gene therapy industry, AI healthcareThe pharmaceutical industry in China after the post-pandemic era is analyzed from five aspects.
Mr. Mao Hua pointed out in his report that globally and in China, there are ongoingDual-specific antibodyClinical trials are concentrated in the field of oncology, but global clinical applications have gradually expanded to non-oncology areas, becoming more diversified. The therapeutic areas for bispecific antibody clinical trials in China will continue to expand. In addition, both global and Chinese bispecific antibody clinical trials are mainly in the early stages, with a higher proportion at the late clinical stage globally. As technology matures, more products from China will be approved for IND (Investigational New Drug) and enter the clinical phase, accelerating clinical progress.
atmRNA technologyOn one hand, Mr. Mao Hua pointed out that mRNA technology is widely applied and has significant advantages. The market demand for mRNA technology is vast, and its successful application in COVID-19 vaccines has attracted much attention, demonstrating its technological advantages and huge market potential in the future.
atsmall nucleic acid drugOn one hand, Mr. Mao Hua stated that large pharmaceutical companies are actively deploying in the field of small nucleic acids through strategic cooperation. In 2016, with the launch of two ASO drugs, the global market for small nucleic acid drugs began to grow rapidly. In the future, as clinical application indications continue to expand and the potential patient population increases, the market size for small nucleic acid drugs will continue to expand.
Mr. Mao Hua said that with the increasing maturity of genetic engineering technology and regulatory systems, globallyCell and Gene TherapyThe market has entered a golden age. The Chinese cell and gene therapy market is still in its early development stages, but a comprehensive regulatory system has been gradually established. Global CGT clinical trials are evolving towards diversified disease areas, currently covering genetic diseases, malignant tumors, infectious diseases, and chronic diseases. Domestic clinical trials in China focus more on tumor treatment, with significant room for future expansion of indications.
Finally,AI healthcareOn one hand, Mr. Mao Hua stated that based on the development of technologies such as machine learning and natural language processing, AI has been applied in multiple scenarios including drug research and development, assisted diagnosis, and health management, and has a rich target market. China's AI health management, AI imaging, and AI drug research and development have successively seen investment peaks, with AI medical robots expected to become new investment hotspots.
After Mr. Mao Hua delivered his keynote report, experts from listed service institutions participating in the forum shared and exchanged the latest developments in the capital market with the attending guests. This included discussions on hot topics such as the SPAC (Special Purpose Acquisition Company) listing mechanism and the listing rules of the Beijing Stock Exchange. They analyzed some hot issues during the listing process of biotech and pharmaceutical companies and looked ahead to the future development trends of the pharmaceutical and healthcare industries.
On September 17th, the Hong Kong Stock Exchange published the 'Consultation Document on the Acquisition of Special Purpose Companies' (''The Consultation Document''), which sought market opinions on the implementation of the SPAC listing mechanism in Hong Kong, sparking heated discussions. Guests engaged in full communication and debate on this topic. Mr. Mao Hua participated in the roundtable discussion and expressed his views on the opportunities and challenges of the Hong Kong Stock Exchange's proposed introduction of the SPAC mechanism. The guests compared the SPAC model, which has a long history of development in the US market, with the recent SPAC models in the UK and Singapore that have been seeking market feedback on improving or introducing the SPAC system. They analyzed and discussed the main considerations for SPAC listing conditions mentioned in the Hong Kong Stock Exchange's 'Consultation Document', including pre-SPC merger and acquisition considerations, standards for target companies in SPAC mergers and acquisitions, etc., from aspects such as industry development impact and investment and financing opportunities.
Mr. Mao Hua, Partner and Managing Director of Frost & Sullivan Greater China, participated in the roundtable discussion
Mr. Mao Hua delivered a speech during the roundtable discussion session
In addition, Ms. Li Qian, Senior Consulting Director of the Healthcare Business Unit at Frost & Sullivan Greater China, participated in the afternoon roundtable discussion session. On behalf of Frost & Sullivan, she provided a professional interpretation of the draft listing rules released by the Beijing Stock Exchange on September 5th. The guests compared the listing conditions with those of other capital markets in Mainland China and, based on their experience serving enterprises listed on other capital markets in Mainland China, especially the New Third Board and Science and Technology Innovation Board, interpreted the listing rules of the Beijing Stock Exchange. They also shared and exchanged views on potential financial, tax, legal, regulatory issues that innovative biotech companies may encounter during the listing process.
Ms. Li Qian, Senior Consulting Director of Healthcare Business Unit in Frost & Sullivan Greater China, participated in the roundtable discussion
Ms. Li Qian spoke during the roundtable discussion session
The conference received widespread attention from participants from biopharmaceutical companies. The series of excellent keynote reports and discussion sessions brought by the experts were highly praised and continuously pursued by the attendees. Frost & Sullivan will continue to leverage its professional expertise in the future, sharing interpretations of China's latest pharmaceutical industry policies and exploring global trends in innovation and development.
